|
Delaware
|
33-0728374
|
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
|
incorporation)
|
Identification No.)
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1. Pursuant to the Dynavax 2004 Non-Employee Directors' Option Plan (the "Directors' Plan"), Dr. Kisner was granted an initial non-qualified stock option to purchase 20,000 shares o f Dynavax common stock, with an exercise price equal to the fair market value on the date of grant, vesting over four years in equal annual installments;
2. Pursuant to the Directors' Plan, Dr. Kisner will be eligible to receive a non-qualified option to purchase up to an additional 10,000 shares of Dynavax common stock at each annual meeting of Dynavax's stockholders (with respect to the first such grant, the option will be pro-rated such that the fraction of such 10,000 shares shall equal the fraction of the year that he serves until the 2011 annual meeting), with an exercise price equal to the fair market value on the date of grant, vesting on the first anniversary of the grant; and
3. Dr. Kisner will receive an annual retainer of $20,000, payable in equal quarterly installments in arrears, $2,000 for each Board meeting attended in person and $500 for each Board meeting attended by telephone.
A copy of the press release relating to Dr. Kisner's appointment is attached hereto as Exhibit 99.1.
|
Dynavax Technologies Corporation
|
||||||||
|
Date: July 22, 2010
|
By:
|
/s/ Jennifer Lew
|
||||||
|
Jennifer Lew
|
||||||||
|
Vice President, Finance
|
||||||||
|
Exhibit No.
|
Description
|
|
|
EX-99.1
|
Press Release, dated July 22, 2010, titled "Dynavax Appoints Daniel Kisner, M.D. to Board of Directors".
|
|
Exhibit 99.1 |
|
DYNAVAX |
|
DYNAVAX TECHNOLOGIES 2929 Seventh Street, Suite 100 Berkeley, CA 94710 |
|
Contact: Michael Ostrach Vice President and Chief Business Officer 510-665-7257 mostrach@dynavax.com |
DYNAVAX APPOINTS DANIEL KISNER, M.D. to BOARD OF DIRECTORS
Berkeley, CA – July 22, 2010 – Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the appointment of Daniel Kisner, M.D. to its Board of Directors. The addition of Dr. Kisner to the Dynavax Board brings its membership to 10.
Dr. Kisner most recently served as a Partner at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies, leading its evolution from a start-up focused on microfluidic lab-on-a-chip technology to a publicly-traded, commercial organization. Prior to Caliper, he was the President and COO of Isis Pharmaceuticals, Inc.
Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology.
Dr. Kisner serves as Chairman of the Board for Tekmira Pharmaceuticals, and he sits on the boards of several private companies. He holds a BA from Rutgers University and an M.D. from Georgetown University. He is a Venture Partner at Aberdare Ventures, a San Francisco, CA-based venture capital firm.
|
About Dynavax |
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.